Compare · KALV vs NVO
KALV vs NVO
Side-by-side comparison of KalVista Pharmaceuticals Inc. (KALV) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KALV and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $203.51B, about 142.3x KALV ($1.43B).
- Over the past year, KALV is up 108.8% and NVO is down 39.5% - KALV leads by 148.3 points.
- KALV has been more active in the news (17 items in the past 4 weeks vs 11 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 8 for KALV).
- Company
- KalVista Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $26.95+0.34%
- $44.05-3.39%
- Market cap
- $1.43B
- $203.51B
- 1M return
- +1.13%
- +4.41%
- 1Y return
- +108.83%
- -39.50%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 17
- 11
- Recent ratings
- 8
- 25
KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical trial for an oral on-demand therapy for acute HAE attacks; and KVD824, an oral product candidate for the treatment of HAE. The company is headquartered in Cambridge, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest KALV
- Amendment: SEC Form SC 14D9/A filed by KalVista Pharmaceuticals Inc.
- CHIEF DEVELOPMENT OFFICER Yea Christopher exercised 33,800 shares at a strike of $7.07 and sold $905,225 worth of shares (33,800 units at $26.78) (SEC Form 4)
- KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
- Chief Commercial Officer Sweeny Nicole sold $39,872 worth of shares (1,489 units at $26.78) and converted options into 5,000 shares, increasing direct ownership by 6% to 59,291 units (SEC Form 4) to cover withholding tax
- CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 5,000 shares and sold $59,955 worth of shares (2,239 units at $26.78), increasing direct ownership by 2% to 150,260 units (SEC Form 4) to satisfy tax liability
- CHIEF DEVELOPMENT OFFICER Yea Christopher converted options into 3,125 shares and sold $52,645 worth of shares (1,966 units at $26.78), increasing direct ownership by 0.51% to 229,918 units (SEC Form 4) (tax liability)
- CHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 23,250 shares and sold $292,646 worth of shares (10,926 units at $26.78), increasing direct ownership by 3% to 479,989 units (SEC Form 4) (tax withholding)
- Chief Commercial Officer Sweeny Nicole converted options into 6,250 shares and sold $49,846 worth of shares (1,861 units at $26.78), increasing direct ownership by 9% to 55,780 units (SEC Form 4) to satisfy tax liability
- CHIEF DEVELOPMENT OFFICER Yea Christopher sold $63,158 worth of shares (2,358 units at $26.78) and converted options into 3,750 shares, increasing direct ownership by 0.61% to 228,759 units (SEC Form 4) to satisfy withholding obligation
- CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 6,250 shares and sold $71,916 worth of shares (2,685 units at $26.78), increasing direct ownership by 2% to 147,499 units (SEC Form 4) to cover withholding tax
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates